<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509275</url>
  </required_header>
  <id_info>
    <org_study_id>W0027-08</org_study_id>
    <nct_id>NCT00509275</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)</brief_title>
  <official_title>A Phase Ib, Randomized, Double Blind, Placebo Controlled Study to Investigate the Pharmacokinetics, Safety and Efficacy of 3 Different Doses of W0027 and Placebo Capsules in Subjects With Clinically and Mycologically Proven MTTP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase Ib, multi-centre, randomized, double-blind, placebo-controlled parallel group
      study, 120 subjects with moccasin type tinea pedis (MTTP) will be enrolled at approximately
      11 centres in the USA, Canada and Australia.

      The primary objective of the study is to assess the patient response to three W0027 regimens
      in subjects with MTTP. Secondary objectives include assessment of the safety, tolerability
      and skin and nail pharmacokinetics to the three Albaconazole regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to assess the subject response to three W0027 regimens in subjects with MTTP.</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of this study are: To assess the safety and tolerability of three W0027 regimens in subjects with MTTP; To assess skin and nail pharmacokinetics of three Albaconazole doses in subjects with MTTP.</measure>
    <time_frame>Skin and Plasma samples Week 0 (Visit 2) through to Week 8 (Visit 9), Nail samples Week 0 (Visit 2) Week 4(Visit 7) and Week 8(Visit 9)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>W0027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>W0027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>W0027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>W0027</intervention_name>
    <description>capsule</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18-65 years, who have been diagnosed with moccasin type tinea pedis (by
             positive dermatophyte culture, positive potassium hydroxide/calcofluor white
             preparation, and a Total Signs and Symptoms Score of at least 4).

          -  Females of childbearing potential must use contraceptive methods .

        Exclusion Criteria:

          -  Subjects who are receiving any CYP3A substrates with potential for QT prolongation;

          -  have used systemic antifungal drugs within 30 days of first dose; or topical
             antifungals within 2 weeks of first dose.

          -  Also excluded are those who have a clinically significant medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynda Spelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South East Dermatology, South East Dermatology, Carina QLD 4152, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Freeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Skin Centre, Benowa QLD 4217, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Foley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin and Cancer Foundation, Carlton VIC 3053 , Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Shumack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George Dermatology and Skin Cancer Centre, Kogarah NSW 2217, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warren Weightman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology on Ward, North Adelaide SA 5006, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Debra Breneman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Dermatology Consultants, Inc., Cincinnati, OH, 45219, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Tschen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albuquerque, NM 87106, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Poulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Dermatologie de Québec Métropolitain, Quebec, QC, G1V 4X7, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Gratton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Dermatology Research Inc., Montreal, QC, H3H 1V4, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne Gulliver Gulliver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NewLab Clinical Research, St. John's, NF, A1B 3E1, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Grekin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>13450 East 12 Mile Road, Warren, MI 48088, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists, 501 South Second Street, Louisville, KY 40202, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Dermatology Consultants, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Dermatology and Skin Cancer Centre</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>NSW 2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>QLD 4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South East Dermatology</name>
      <address>
        <city>Carina</city>
        <state>Queensland</state>
        <zip>QLD 4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology on Ward</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>SA 5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Foundation</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>VIC 3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

